Pay in 4 interest-free payments of $6.78 Learn more
:format(webp))
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Pathway 2: Chronic weight management (approved November 2023, marketed as Zepbound) You qualify if you have: BMI 30 kg/m or higher (obesity), OR BMI 27 kg/m or higher (overweight) with at least one weight-related comorbid condition The weight management indication uses the brand name Zepbound rather than Mounjaro, but the active ingredient (tirzepatide) and dosing are identical
When in doubt, contact your pharmacist before using the medication
As body composition changes and insulin sensitivity improves, patients may experience shifts in various hormones that regulate sleep, including cortisol, growth hormone, and leptin
Manage any gastrointestinal side effects proactively
Technology Appraisal TA875: Semaglutide for managing overweight and obesity
US$ 22.21
US$ 26.64
US$ 24.70
US$ 22.89
US$ 23.48
